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The vision
Effective and humane treatment for all people 
with drug use disorders. Nothing less than 
would be expected for any other disease. 
UNODC-WHO Joint Programme on 
What are our aims?  
To promote policies that strike the right balance between the reduction of drug supply and demand, 
and incorporate science-based drug prevention and dependence treatment.
Humane and accessible treatment and care for more people with drug dependence and drug-related 
diseases (particularly HIV/AIDS) that will result in opportunities for rehabilitation and reintegration 
into society.
Essential services based on scientifi c evidence which provide a recovery-oriented continuum of care, 
matching the needs of dependent drug users in all social, motivational and clinical stages. 
 
Partners in action
The programme is based on a global collaborative effort, under the leadership of UNODC and WHO. 
The collaboration will include governments, health professionals, non-governmental organizations 
(NGOs) and funding agencies committed to increasing the coverage of essential services for drug 
dependence treatment and care. 
Why UNODC and WHO together? 
UNODC and WHO both have constitutional mandates to address issues presented by drug use and 
dependence. Moreover, taking into account the health, socio-economic and security implications of drug 
use and related disorders, the two agencies are uniquely positioned to lead this initiative. In particular, 
it will open a dialogue with Member States and involve a varied group of government ministries such as 
those for health, welfare, as well as the criminal justice system and other relevant sectors. 
This initiative is closely linked to the Mental Health Gap Action Programme (mhGAP), which was set up 
by WHO in November 2008 to identify strategies for scaling up care for mental, neurological and 
substance use disorders. This includes disorders due to illicit drug use as one of eight priority conditions.
Monitoring and evaluation
The programme includes the development of monitoring and evaluation tools on drug dependence 
UNODC-WHO programme.
• Output indicators for the monitoring and evaluation of the programme’s implementation of 
its objectives.
for 2009-2013. 
 
Nothing less than what is expected for the treatment 
and care of any other disease.
The Joint UNODC-WHO Programme on Drug Dependence Treatment and Care is a milestone in the 
for illicit substances, relieve suffering and decrease drug-related harm to individuals, families, 
communities and societies. 
drug use disorders in a pragmatic, science-based and humanitarian way, replacing stigma and 
discrimination with knowledge, care, recovery opportunities and re-integration.
35.3% 
31.2%
12.4%
9.8% 
11.3%
54% 
30.8% 
2.6% 
2.2% 
10.4% 
60.1%
18.9%
11.9% 
9.1% 
63.6% 15.7% 
9.6% 
5.2% 
47.3% 
32.6% 
18.2% 
0.4%
 C
o
cain
e 
1.5%
0.4%
 Cocaine 
ASIA
EUROPE
N. AMERICA
S. AMERICA
AFRICA
OCEANIA
Unweighted average of treatment
demand (2001-2006) in Canada,
Mexico and the USA. 
Unweighted average of
treatment demand in 24
countries of South America,
Central America and the
Caribbean, 1998-2006.
Unweighted average of
treatment demand in 39
European countries in
2000-2006.
Unweighted average of
treatment demand in 41
African countries in
1994 - 2006.
Unweighted average of
treatment demand in
Australia and New Zealand
2004-2006.
Unweighted average of
treatment demand in
41 Asian countries and
territories in 1994-2006.
5.9%
63.3% 
19.1%
11.5% 
5.7%
Sources: UNODC, Annual Reports Questionnaire Data/DELTA and National Government Reports.
Cannabis
Opiates
Amphetamine-type
stimulants
Cocaine-type
Others
No data available
Main problem drugs (as reflected in treatment demand), 2006 (or latest year available)
Note: Data generally account for primary drug use; therefore polydrug use may increase totals beyond 100%. 
The facts 
Drug use and dependence is a public health issue 
with a serious impact on development and 
security. An estimated 205 million people in the 
world use illicit drugs, of whom some 25 million 
are drug dependent. 
Drug use is one of the top 20 risk factors to health 
worldwide and among the top 10 in developed 
countries. Drug use disorders are associated 
with an increased risk of other diseases such as 
HIV/AIDS, hepatitis, tuberculosis, suicide, 
overdose deaths and cardiovascular diseases. 
Injecting drug use is a major route of HIV 
and hepatitis transmission in many regions. 
Approximately 3 million injecting drug users 
are HIV positive. Outside of sub-Saharan Africa, 
30 per cent of global HIV infections are due to 
this cause.
When criminal activities related to drug use are 
included, the economic cost of drug use and 
dependence in some countries can amount to 
2 per cent of GDP.
Effective treatment and care
• Drug dependence can often be treated 
effectively with low-cost medications and 
simple psychological interventions.
• Treatment of drug dependence can be 
integrated into primary health care.
• Non-specialist health providers can deliver 
specifi c mental health interventions with 
appropriate training.
• For $US 1 invested in evidence-based 
treatment, up to $US 6 are saved in terms of 
costs for health, security and welfare.
The objectives
• The promotion and support worldwide (with a particular 
focus on low- and middle-income countries) of evidence-
based policies, strategies and interventions that are based on a 
public health and human rights approach, in order to reduce 
drug use and the health and social burden it causes.
• The widespread recognition of drug dependence as a 
preventable and treatable multifactorial health disorder, and 
recognition of the social advantages of investing in treatment, 
such as lowering health-related costs, improving security and 
contributing to social cohesion and development. 
• Drug dependence treatment should become a part of the 
mainstream health care and social welfare system, without 
discrimination with respect to other chronic general and 
mental health disorders. Nothing less than what is provided 
for other diseases.
• The investment in comprehensive and results-oriented 
programmes for drug dependence treatment and care, 
particularly community-based interventions, including the 
skill set of their human resources. 
Improving access
In order to increase access, improve retention and reduce relapse 
rates, services developed under the Joint Programme are designed 
to respond to the needs of a variety of patients in a recovery-
oriented continuum of care including: 
• Outreach interventions for dependent individuals not 
motivated to treatment.
• Clinical interventions to stop or reduce the use of drugs, 
control addictive behaviour, restore interpersonal relationships, 
improve social, emotional and professional skills. 
• Low-threshold activities targeting HIV (AIDS) and hepatitis 
and providing health and social care.
• Longer-term interventions aiming at recovery and 
reintegration into society. 
7. Provides alternative measures to imprisonment for dependent 
drug users where appropriate and, where this is not possible, 
provision of drug dependence treatment in prison settings.
8. Supports universities at the national level to promote research 
and training curricula on drug dependence treatment and care.
9. Provides and supports training programmes for professionals 
involved in the provision of treatment and care for drug users, 
including those whose professional primary focus is not in 
that area.
10. Develops international recommendations, guidelines and 
standards aiming at the knowledge transfer from research to 
practice and supports adaptation and implementation at 
country level.
11. Supports regional networks of quality service providers, 
working on drug dependence treatment, social support services 
and HIV/AIDS prevention and care.
Use of resources
The budget of the Joint Programme is almost entirely spent at the 
country and regional level. More than 80 per cent of resources are 
devoted to cover the cost of activities in the selected countries to 
reach people in need of treatment. Although the programme has a 
global dimension and coordination, a country-oriented approach 
focused on regional delivery of services permits most of the 
resources to be spent quickly and effectively through the direct 
involvement of governments, UNODC Field Offi ces and WHO 
Country Offi ces.
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The Joint Programme
 1. Leads a global collaborative effort for improving coverage and 
quality of treatment and care services for drug use disorders in 
low- and middle-income countries.
2. Promotes the development of comprehensive and integrated 
treatment systems that are able to deliver a continuum of care 
for drug users and link services at municipal and national levels.
3. Maps population needs, legislative frameworks and available 
services and programmes for drug dependence treatment 
and care. 
4. Supports policy and legislation revision to achieve balance in drug 
policy and to support humane and effective drug prevention, 
treatment and care.
5. Develops low-cost outreach treatment and care services, and 
increases access in rural and remote areas.
6. Places prevention, treatment and care of drug use disorders into 
the mainstream health care system, linking with NGOs and 
ensuring full coordination with the health care system, as part 
of an integrated continuum of care. 
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(NGOs) and funding agencies committed to increasing the coverage of essential services for drug 
dependence treatment and care. 
Why UNODC and WHO together? 
UNODC and WHO both have constitutional mandates to address issues presented by drug use and 
use and related disorders, the two agencies are uniquely positioned to lead this initiative. In particular, 
it will open a dialogue with Member States and involve a varied group of government ministries such as 
those for health, welfare, as well as the criminal justice system and other relevant sectors. 
by WHO in November 2008 to identify strategies for scaling up care for mental, neurological and 
substance use disorders. This includes disorders due to 
Monitoring and evaluation
The programme includes the development of monitoring and evaluation tools on drug dependence 
treatment and care, with a set of indicators and monitoring mechanisms that cover the following domains: 
• Input indicators for monitoring level and scope of country support provided in the framework of the 
UNODC-WHO programme.
• Output indicators for the monitoring and evaluation of the programme’s implementation of 
its objectives.
• Outcome indicators for monitoring progress towards the overall aim of the initiative and action plan 
for 2009-2013. 
 
Nothing less than what is expected for the treatment 
and care of any other disease.
The Joint UNODC-WHO Programme on Drug Dependence Treatment and Care is a milestone in the 
development of a comprehensive, integrated health-based approach to drug policy that can reduce demand 
for illicit substances, relieve suffering and decrease drug-related harm to individuals, families, 
communities and societies. 
The initiative sends a strong message to policymakers regarding the need to develop services that address 
drug use disorders in a pragmatic, science-based and humanitarian way, replacing stigma and 
discrimination with knowledge, care, recovery opportunities and re-integration.
